PMID- 38075571
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231211
IS  - 2307-8960 (Print)
IS  - 2307-8960 (Electronic)
IS  - 2307-8960 (Linking)
VI  - 11
IP  - 33
DP  - 2023 Nov 26
TI  - Influence of ganglioside combined with methylprednisolone sodium succinate on 
      efficacy and neurological function in patients with acute myelitis.
PG  - 7972-7979
LID - 10.12998/wjcc.v11.i33.7972 [doi]
AB  - BACKGROUND: Acute myelitis (AM) can lead to sudden sensory, motor and autonomic 
      nervous dysfunction, which negatively affects their daily activities and quality 
      of life, so it is necessary to explore optimization from a therapeutic 
      perspective to curb the progression of the disease. AIM: To investigate the 
      effect of ganglioside (GM) combined with methylprednisolone sodium succinate 
      (MPSS) on the curative effect and neurological function of patients with AM. 
      METHODS: First, we selected 108 AM patients visited between September 2019 and 
      September 2022 and grouped them based on treatment modality, with 52 patients 
      receiving gamma globulin (GG) + MPSS and 56 patients receiving GM + MPSS, 
      assigned to the control group (Con) and observation group (Obs), respectively. 
      The therapeutic effect, neurological function (sensory and motor function 
      scores), adverse events (AEs), recovery (time to sphincter function recovery, 
      time to limb muscle strength recovery above grade 2, and time to ambulation), 
      inflammatory factors (IFs) [interleukin (IL)-6, C-reactive protein (CRP), and 
      tumor necrosis factor (TNF)-alpha] and other data of the two groups were collected 
      for evaluation and comparison. RESULTS: The Obs had: (1) A significantly higher 
      response rate of treatment than the Con; (2) Higher scores of sensory and motor 
      functions after treatment that were higher than the baseline (before treatment) 
      and higher than the Con levels; (3) Lower incidence rates of skin rash, 
      gastrointestinal discomfort, dyslipidemia, osteoporosis and other AEs; (4) Faster 
      posttreatment recovery of sphincter function, limb muscle strength and 
      ambulation; and (5) Markedly lower posttreatment IL-6, CRP and TNF-alpha levels than 
      the baseline and the Con levels. CONCLUSION: From the above, it can be seen that 
      GM + MPSS is highly effective in treating AM, with a favorable safety profile 
      comparable to that of GG + MPSS. It can significantly improve patients' 
      neurological function, speed up their recovery and inhibit serum IFs.
CI  - (c)The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights 
      reserved.
FAU - Sun, Yu-Fei
AU  - Sun YF
AD  - Department of Special Medicine, Basic Medical College of Qingdao University, 
      Qingdao 266071, Shandong Province, China.
FAU - Liu, Li-Li
AU  - Liu LL
AD  - Department of Medical Microbiology, Basic Medical College of Qingdao University, 
      Qingdao 266075, Shandong Province, China.
FAU - Jiang, Sha-Sha
AU  - Jiang SS
AD  - Department of Medical Microbiology, Basic Medical College of Qingdao University, 
      Qingdao 266075, Shandong Province, China.
FAU - Zhang, Xian-Juan
AU  - Zhang XJ
AD  - Department of Clinical Laboratory, The Affiliated Hospital of Qingdao University, 
      Qingdao 266000, Shandong Province, China.
FAU - Liu, Feng-Jun
AU  - Liu FJ
AD  - Department of Special Medicine, School of Basic Medicine, Qingdao University, 
      Qingdao 266000, Shandong Province, China.
FAU - Zhang, Wan-Ming
AU  - Zhang WM
AD  - Department of Special Medicine, Basic Medical College of Qingdao University, 
      Qingdao 266071, Shandong Province, China. zhangwanming0532@126.com.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - World J Clin Cases
JT  - World journal of clinical cases
JID - 101618806
PMC - PMC10698404
OTO - NOTNLM
OT  - Acute myelitis
OT  - Ganglioside
OT  - Methylprednisolone sodium succinate
OT  - Neurological function
OT  - Therapeutic effect
COIS- Conflict-of-interest statement: All the authors report no relevant conflicts of 
      interest for this article.
EDAT- 2023/12/11 06:45
MHDA- 2023/12/11 06:46
PMCR- 2023/11/26
CRDT- 2023/12/11 05:59
PHST- 2023/09/13 00:00 [received]
PHST- 2023/10/11 00:00 [revised]
PHST- 2023/10/30 00:00 [accepted]
PHST- 2023/12/11 06:46 [medline]
PHST- 2023/12/11 06:45 [pubmed]
PHST- 2023/12/11 05:59 [entrez]
PHST- 2023/11/26 00:00 [pmc-release]
AID - 10.12998/wjcc.v11.i33.7972 [doi]
PST - ppublish
SO  - World J Clin Cases. 2023 Nov 26;11(33):7972-7979. doi: 
      10.12998/wjcc.v11.i33.7972.